Accordingly, nivolumab, an inhibitor of PD-1 exhibited positive results in patients with advanced HCC with or without chronic viral hepatitis [10], although the overall therapeutic effect remains still unsatisfactory. Here, PDCD1 is linked to hepatocellular carcinoma.